Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07204392

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

Status
Recruiting
Phase
Study type
Observational
Enrollment
313 (estimated)
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN. In this study, we would like to define the germline predisposition to MPN.

Conditions

Timeline

Start date
2022-06-27
Primary completion
2030-12-31
Completion
2030-12-31
First posted
2025-10-02
Last updated
2025-10-02

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT07204392. Inclusion in this directory is not an endorsement.

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms (NCT07204392) · Clinical Trials Directory